AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
-Enrolled patients allowed to continue on study- MENLO PARK, Calif.–(BUSINESS WIRE)–AN2 Therapeutics, Inc. (Nasdaq: ANTX),